Senolytic Research Timeline: From Mayo Clinic to Global Trials
Expert Summary
The senolytic field progressed with unusual speed from animal model proof-of-concept (2011) to first human trial (2019) to global multi-site trials (2022–2025). The Mayo Clinic has been the primary institutional driver, with collaborating groups at the Scripps Research Institute, University of Texas Health, University of Minnesota, and international partners.
Key Facts
- 2011: Baker et al. (Nature) demonstrate that clearing p16-positive senescent cells delays disease in progeroid mice. Proof of principle that senescent cell clearance is therapeutically meaningful.
- 2015: Zhu et al. (Aging Cell) identify the first senolytic drugs using transcriptomic analysis of senescent cell survival networks: navitoclax (BCL-2 inhibitor) and the D+Q combination.
- 2017: Zhu et al. (Aging) report that fisetin and two BCL-XL inhibitors have senolytic activity — opening the natural senolytic field.
- 2018: Yousefzadeh et al. (EBioMedicine) demonstrate fisetin extends median lifespan 10% in late-life-treated mice and reduces senescent cell burden. Scripps Research milestone for natural senolytics.
- 2018/2019: Xu et al. (Nature Medicine) publish the first human D+Q trial in IPF — first peer-reviewed evidence of senolytic activity in human tissue.
- 2019–2020: Multiple Phase 2 trials launch: DKD, frailty in elderly, Alzheimer's, pulmonary fibrosis progression.
- 2021: Justice et al. publish frailty trial results showing significant gait speed improvement with D+Q. PEARL fisetin trial reports preliminary senescence biomarker reductions.
- 2022–2025: ALSENLITE (Alzheimer's), WISDOM (frailty prevention), SPERMAGE (biological age clock) trials ongoing. International expansion to Europe, Australia, Japan.
Recommended Products
Frequently Asked Questions
Which institution has contributed most to senolytic research?
The Mayo Clinic Kogod Center on Aging (James Kirkland's lab) has been the most prolific contributor: discovering D+Q senolytic combination, running first human trials, and establishing most of the clinical trial infrastructure for the field.
When might senolytics be commercially available as drugs?
If current Phase 2/3 trials succeed, prescription senolytic drugs could reach FDA approval within 5–10 years. However, fisetin and quercetin are available now as supplements — albeit without FDA drug approval status.
Scientific References
- Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011. PMID: 22048312
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130